Literature DB >> 18280851

Medication use in the neonatal intensive care unit: current patterns and off-label use of parenteral medications.

Praveen Kumar1, Jennifer K Walker, Kristin M Hurt, Kimberly M Bennett, Neal Grosshans, Michael A Fotis.   

Abstract

OBJECTIVES: To study the current patterns of medication use, assess the extent of off-label parenteral medication use, and evaluate evidence for efficacy and safety of parenteral medications used off-label in neonates. STUDY
DESIGN: We collected information on all medications dispensed for infants admitted to an urban tertiary care neonatal intensive care unit over a 3-year period. Parenteral drugs were reviewed for off-label use, and medications not approved for use in neonates were evaluated for evidence of efficacy and safety in neonates.
RESULTS: The ranges of gestational age, length of stay, and number of medications per infant were 23 to 42 weeks, 1 to 190 days, and 1 to 62, respectively, for 2304 admissions during the study period. Infants with lower birth weight and shorter gestational age received more medications compared with more mature infants. Of 61 parenteral medications evaluated, 27 (45%) were used off-label in neonates. Food and Drug Administration (FDA) approval for use in neonatal period was highest for antibiotics (14/16); the parenteral medications most frequently used off-label were analgesics, vasopressors, and hematologic agents.
CONCLUSIONS: Critically ill neonates are exposed to numerous medications, a significant proportion of which are not yet FDA-approved for use in this vulnerable group of patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18280851     DOI: 10.1016/j.jpeds.2007.07.050

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  33 in total

1.  Drug utilisation profile in the neonatal unit of a university hospital: a prospective observational study in Brazil.

Authors:  Adriana Cristina de Souza Gonçalves; Adriano Max Moreira Reis; Ana Carolina Marçal Gusmão; Maria Cândida Ferrarez Bouzada
Journal:  Int J Clin Pharm       Date:  2015-04-02

2.  Evaluating the accuracy of electronic pediatric drug dosing rules.

Authors:  Eric S Kirkendall; S Andrew Spooner; Judith R Logan
Journal:  J Am Med Inform Assoc       Date:  2013-06-28       Impact factor: 4.497

3.  Cross-over trial of treatment for bradycardia attributed to gastroesophageal reflux in preterm infants.

Authors:  Eva Wheatley; Kathleen A Kennedy
Journal:  J Pediatr       Date:  2009-06-21       Impact factor: 4.406

Review 4.  Two decades of off-label prescribing in children: a literature review.

Authors:  Shamala Balan; Mohamed Azmi Ahmad Hassali; Vivienne S L Mak
Journal:  World J Pediatr       Date:  2018-09-14       Impact factor: 2.764

5.  Sedation and analgesia in mechanically ventilated preterm neonates: continue standard of care or experiment?

Authors:  Christopher McPherson
Journal:  J Pediatr Pharmacol Ther       Date:  2012-10

6.  Neonatal Safety Information Reported to the FDA During Drug Development Studies.

Authors:  Debbie Avant; Gerri Baer; Jason Moore; Panli Zheng; Alfred Sorbello; Ron Ariagno; Lynne Yao; Gilbert J Burckart; Jian Wang
Journal:  Ther Innov Regul Sci       Date:  2017-06-28       Impact factor: 1.778

Review 7.  How to optimize the evaluation and use of antibiotics in neonates.

Authors:  Evelyne Jacqz-Aigrain; Florentia Kaguelidou; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-09-01       Impact factor: 3.278

8.  Off-label and unlicensed drug use in hospitalized newborns in a Saudi tertiary care hospital: a cohort study.

Authors:  Faizan Mazhar; Shahzad Akram; Nafis Haider; Muhammad Abdul Hadi; Jabeen Sultana
Journal:  Int J Clin Pharm       Date:  2018-05-02

Review 9.  Neonatal pain control and neurologic effects of anesthetics and sedatives in preterm infants.

Authors:  Christopher McPherson; Ruth E Grunau
Journal:  Clin Perinatol       Date:  2013-12-17       Impact factor: 3.430

10.  Cimetidine-associated patent ductus arteriosus is mediated via a cytochrome P450 mechanism independent of H2 receptor antagonism.

Authors:  Robert B Cotton; Lisa P Shah; Stanley D Poole; Noah J Ehinger; Naoko Brown; Elaine L Shelton; James C Slaughter; H Scott Baldwin; Bibhash C Paria; Jeff Reese
Journal:  J Mol Cell Cardiol       Date:  2013-02-27       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.